Reproterol

Reproterol is a dual acting β2-adrenoceptor agonist and PDE inhibitor. The theophylline constituent of Reproterol inhibits phosphodiesterase activity induced by adenylyl cyclase. Reproterol has the potential for asthma research[1][2].

Product Specifications

CAS Number

[54063-54-6]

UNSPSC

12352005

Target

Adrenergic Receptor; Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/reproterol.html

Purity

96.62

Solubility

DMSO : 3.9 mg/mL (ultrasonic; warming)

Smiles

O=C(N1C)N(C)C2=C(N(CCCNCC(C3=CC(O)=CC(O)=C3)O)C=N2)C1=O

Molecular Formula

C18H23N5O5

Molecular Weight

389.41

References & Citations

[1]Uwe R Juergens, et al. Different mechanisms of action of beta2-adrenergic receptor agonists: a comparison of reproterol, fenoterol and salbutamol on monocyte cyclic-AMP and leukotriene B4 production in vitro. Eur J Med Res. 2004 Jul 30;9 (7) :365-70.|[2]C G Georgakopoulos, et al. Excretion study of the beta2-agonist reproterol in human urine. J Chromatogr B Biomed Sci Appl. 1999 Apr 16;726 (1-2) :141-8.